HU210834B - Method for the preparation pharmaceutical composition for the treatment of dermatitis - Google Patents
Method for the preparation pharmaceutical composition for the treatment of dermatitis Download PDFInfo
- Publication number
- HU210834B HU210834B HU91511A HU51191A HU210834B HU 210834 B HU210834 B HU 210834B HU 91511 A HU91511 A HU 91511A HU 51191 A HU51191 A HU 51191A HU 210834 B HU210834 B HU 210834B
- Authority
- HU
- Hungary
- Prior art keywords
- nctc
- pharmaceutical composition
- treatment
- dermatitis
- bacterial
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 6
- 201000004624 Dermatitis Diseases 0.000 title description 4
- 239000006166 lysate Substances 0.000 claims description 18
- 230000001580 bacterial effect Effects 0.000 claims description 17
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 241000588653 Neisseria Species 0.000 claims description 6
- 241000606768 Haemophilus influenzae Species 0.000 claims description 4
- 241000588744 Klebsiella pneumoniae subsp. ozaenae Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 4
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 4
- 241001312524 Streptococcus viridans Species 0.000 claims description 4
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 4
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000606790 Haemophilus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 239000004251 Ammonium lactate Substances 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940059265 ammonium lactate Drugs 0.000 description 1
- 235000019286 ammonium lactate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH497/90A CH680045A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-02-16 | 1990-02-16 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU910511D0 HU910511D0 (en) | 1991-09-30 |
| HUT61201A HUT61201A (en) | 1992-12-28 |
| HU210834B true HU210834B (en) | 1995-08-28 |
Family
ID=4188357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU91511A HU210834B (en) | 1990-02-16 | 1991-02-15 | Method for the preparation pharmaceutical composition for the treatment of dermatitis |
Country Status (13)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2098109C1 (ru) * | 1996-09-26 | 1997-12-10 | Александр Григорьевич Чучалин | Противоаллергическое, противовоспалительное средство, способ его получения, лечебное и косметическое средства с его использованием |
| WO1999048510A1 (fr) * | 1998-03-24 | 1999-09-30 | Tayca Corporation | Inhibiteur de la production d'anticorps d'immunoglobuline m et medicament contre la polyarthrite rhumatoide |
| JP2008529960A (ja) | 2003-06-23 | 2008-08-07 | バイオテック トゥールス ソシエテ アノニム | エピトープ組成物 |
| UA72065C2 (en) * | 2004-09-10 | 2005-01-17 | Viridans Ltd Liability Company | Strain aerococcus viridans 167k imb b-7069 with antibacterial activity and "viabac" preparation comprising this strain |
| FR2969657B1 (fr) * | 2010-12-22 | 2014-02-07 | Fabre Pierre Dermo Cosmetique | Nouvelle bacterie et extraits de ladite bacterie et leur utilisation en dermatologie |
| GB201318170D0 (en) * | 2013-10-14 | 2013-11-27 | Univ Edinburgh | Proteins with Diagnostic and Therapeutic Uses |
| EP3960191A4 (en) * | 2019-04-26 | 2023-01-04 | MD Healthcare Inc. | PROTEIN DERIVED FROM STREPTOCOCCUS PYOGENES BACTERIA AND ITS USE |
| KR102437436B1 (ko) | 2019-04-26 | 2022-08-30 | 주식회사 엠디헬스케어 | 스트렙토코커스 파이오제네스 세균 유래 단백질 및 이의 용도 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH633188A5 (fr) * | 1978-05-26 | 1982-11-30 | Om Laboratoires Sa | Medicament contre des maladies infectieuses des voies respiratoires. |
-
1990
- 1990-02-16 CH CH497/90A patent/CH680045A5/fr not_active IP Right Cessation
-
1991
- 1991-02-13 KR KR1019910002437A patent/KR0169982B1/ko not_active Expired - Fee Related
- 1991-02-14 EG EG9191A patent/EG19540A/xx active
- 1991-02-14 IT ITMI910381A patent/IT1244743B/it active IP Right Grant
- 1991-02-15 FR FR9102058A patent/FR2658419B1/fr not_active Expired - Fee Related
- 1991-02-15 DE DE4104728A patent/DE4104728C2/de not_active Expired - Fee Related
- 1991-02-15 BE BE9100144A patent/BE1005589A3/fr active
- 1991-02-15 HU HU91511A patent/HU210834B/hu not_active IP Right Cessation
- 1991-02-15 PL PL28908491A patent/PL289084A1/xx unknown
- 1991-02-15 JP JP3022109A patent/JP3002552B2/ja not_active Expired - Lifetime
- 1991-02-15 PT PT96789A patent/PT96789B/pt not_active IP Right Cessation
- 1991-02-15 GB GB9103278A patent/GB2240922A/en not_active Withdrawn
- 1991-02-15 AT AT0032291A patent/AT402152B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE4104728C2 (de) | 1999-01-14 |
| GB2240922A (en) | 1991-08-21 |
| JP3002552B2 (ja) | 2000-01-24 |
| JPH04211017A (ja) | 1992-08-03 |
| ATA32291A (de) | 1996-07-15 |
| PL289084A1 (en) | 1991-11-04 |
| GB9103278D0 (en) | 1991-04-03 |
| FR2658419B1 (fr) | 1995-01-27 |
| BE1005589A3 (fr) | 1993-11-16 |
| PT96789B (pt) | 1998-08-31 |
| HUT61201A (en) | 1992-12-28 |
| FR2658419A1 (fr) | 1991-08-23 |
| KR910015306A (ko) | 1991-09-30 |
| KR0169982B1 (ko) | 1999-02-01 |
| PT96789A (pt) | 1991-10-31 |
| AT402152B (de) | 1997-02-25 |
| ITMI910381A0 (it) | 1991-02-14 |
| IT1244743B (it) | 1994-08-08 |
| DE4104728A1 (de) | 1991-08-22 |
| HU910511D0 (en) | 1991-09-30 |
| ITMI910381A1 (it) | 1992-08-14 |
| EG19540A (en) | 1995-08-30 |
| CH680045A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69930944T2 (de) | Bacillus coagulans-zusammensetzung und deren verwendung | |
| Pines et al. | Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis | |
| Altz-Smith et al. | Cryptococcosis associated with low-dose methotrexate for arthritis | |
| CN119656205A (zh) | 用于口腔护理的自成膜组合物 | |
| CN113957006A (zh) | 一种植物乳杆菌n13及其在预防或治疗龋齿和牙周炎上的应用 | |
| Sydnor et al. | Comparative evaluation of cefuroxime axetil and cefaclor for treatment of acute bacterial maxillary sinusitis | |
| Punt et al. | Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG) | |
| US4873090A (en) | Non-adjuvenated vaccine | |
| HU210834B (en) | Method for the preparation pharmaceutical composition for the treatment of dermatitis | |
| HUT61478A (en) | Process for producing pharamceutical composition suitable for treating diarrhoae caused by clostridium difficile and by pseudomembranous colitis | |
| Fahy et al. | Bacteraemia and fungaemia in adults with cystic fibrosis | |
| Clark et al. | Effect of commonly prescribed liquid medications on Streptococcus mutans biofilm. An in vitro study | |
| Rodriguez et al. | Ceftazidime in the treatment of meningitis in infants and children over one month of age | |
| Lasemi et al. | Complications of antibiotic therapy and introduction of nanoantibiotics | |
| HU180005B (en) | Process for producing pharmaceutical composition utilizable for treating illnesses of respiratory organs | |
| ROBERTS et al. | Demethylchlortetracycline and Tetracycline: A Critical Comparison: In Vitro Activity, Serum Concentrations, and Effect of Serum Binding | |
| Brodie et al. | Bacterial endocarditis due to an unusual species of encapsulated Neisseria: Neisseria mucosa endocarditis | |
| US20050201952A1 (en) | Treatment and prevention of viral hepatitis infections | |
| Nemeth et al. | Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis | |
| US4287173A (en) | Vaccine for dental caries | |
| AU577941B2 (en) | Non-adjuvenated vaccine | |
| WO1993023015A1 (en) | Liposomal aminoglycoside compositions and process for their preparation | |
| FR2550707A1 (fr) | Medicament immunomodulateur d'origine biologique et son procede de preparation | |
| US20030109565A1 (en) | Antipyretic preparation containing xylitol | |
| EP3015109B1 (en) | Biological barrier with simethicone for the use in the treatment of naso-pharyngo-tubal infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HMM4 | Cancellation of final prot. due to non-payment of fee |